N-[3-[bis(1-hydroxyethyl)amino]propyl]prop-2-enamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-[3-[bis(1-hydroxyethyl)amino]propyl]prop-2-enamide
• 化学式: C₁₀H₂₀N₂O₃
• 分子量: 216.28
• InChiKey: LTQVGSFYGUXOJA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  15
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  72.8
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Aryl boronate functionalized polymers for treating obesity
  申请人：Holmes-Farley Randall Stephen

  公开号：US20060128663A1

  公开（公告）日：2006-06-15

  Disclosed are polymers comprising one or more phenyl boronate ester, boronamide or boronate thioester groups. The phenyl boronate ester, boronamide and boronate thioester groups are represented by one of the following structural formulas: Ar in Structural Formulas (I) and (II) is substituted or unsubstituted; and each Z is —O—, —NH— or —S— and is independently selected. Pharmaceutically acceptable salts of the polymer are also included. The aryl boronate ester, boronamide or boronate thioester can be cleaved to release the corresponding aryl boronic acid. Also disclosed are pharmaceutical compositions comprising the polymers of the present invention and a pharmaceutically acceptable carrier or diluent; and methods of treating a subject for obesity with the polymers of the present invention.

  本发明涉及一种聚合物，其包含一个或多个苯基硼酸酯、硼酰胺或硼酸硫酯基团。苯基硼酸酯、硼酰胺和硼酸硫酯基团由以下结构式之一表示：结构式（I）和（II）中的Ar是取代或未取代的；每个Z是—O—、—NH—或—S—，并且是独立选择的。本发明还包括该聚合物的药学上可接受的盐。芳基硼酸酯、硼酰胺或硼酸硫酯可被裂解以释放相应的芳基硼酸。本发明还涉及包含本发明聚合物和药学上可接受的载体或稀释剂的制药组合物；以及使用本发明聚合物治疗肥胖症的方法。
• Ultra-fine particulated polymer latex and composition containing the same
  申请人：LION CORPORATION

  公开号：EP0273605A2

  公开（公告）日：1988-07-06

  An ultra-fine particulated polymer latex having an average particle size of 100 nm or less, a crosslinked structure and a glass transition temperature lower than a value calculated by a weight fraction method.

  一种超细颗粒聚合物胶乳，其平均粒径为 100 纳米或更小，具有交联结构，玻璃化转变温度低于按重量分数法计算的值。
• Fat-binding polymers
  申请人：GelTex Pharmaceuticals, Inc.

  公开号：US20030039626A1

  公开（公告）日：2003-02-27

  The present invention provides fat-binding polymers, which comprise dialkanolamine, dialkanolammonium, aminoalkylpolyol, and ammoniumalkylpolyol pendant groups for subjects in need of fat removal from the gastrointestinal tract, particularly subjects suffering from steatorrhea and/or experiencing side effects from lipase inhibitors. Patients being administered with lipase inhibitors are typically being treated for Type II Diabetes, streatorrhea, and hypertriglyceridemia. The fat binding polymers of this invention are also suitable for use with obese subjects.

  本发明提供了由二烷醇胺、二烷醇铵、氨基烷基多元醇和烷基多元醇铵悬垂基团组成的脂肪结合聚合物，适用于需要从胃肠道清除脂肪的受试者，特别是患有脂肪泻和/或有脂肪酶抑制剂副作用的受试者。使用脂肪酶抑制剂的患者通常需要治疗 II 型糖尿病、胃食管返流和高甘油三酯血症。本发明的脂肪结合聚合物也适用于肥胖症患者。
• FAT-BINDING POLYMERS
  申请人：GENZYME CORPORATION

  公开号：EP1404349B1

  公开（公告）日：2008-10-22
• ARYL BORONATE FUNCTIONALIZED POLYMERS FOR TREATING OBESITY
  申请人：Geltex Pharmaceuticals, Inc.

  公开号：EP1404686A1

  公开（公告）日：2004-04-07